🇺🇸 FDA

Intelligence · Clinical Pipeline

Infectious disease · Phase II

Infectious disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
375

Quick answer

Infectious disease Phase II programs: NovaPharmaNews indexes 375 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 8

  1. HEC96719

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  2. HEPCLUDEX 2 mg powder for solution for injection, VIR-2218, VIR-3434

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  3. HH-003(20mg/kg)

    Huahui Health

    Chronic Hepatitis Delta Virus Infection

    phase 2 mab completed

    1 trial

  4. Hepatitis A Vaccine

    Takeda

    Healthy Volunteers

    phase 2 mab completed

    1 trial

  5. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  6. Human COVID-19 immunoglobulin (pH4) for intravenous injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  7. Hydroxychloroquine (HCQ)

    Teva Pharma GmbH

    COVID-19

    phase 2 small molecule terminated

    1 trial

  8. IMC-M113V

    Immunocore Ireland Limited

    Chronic HIV infection

    phase 2 small molecule active

    1 trial

  9. INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM

    Pari Pharma GmbH

    Sepsis

    phase 2 small molecule active

    1 trial

  10. ION224

    IONIS PHARMACEUTICALS INC

    Steatohepatitis, Nonalcoholic

    phase 2 small molecule completed

    1 trial

  11. IONIS-HBVRx

    IONIS PHARMACEUTICALS INC

    Hepatitis B

    phase 2 small molecule completed

    1 trial

  12. ISIS 14803

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  13. ISIS 14803, peginterferon alfa, ribavirin

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  14. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Covid19

    phase 2 small molecule completed

    1 trial

  15. Ibezapolstat

    Acurx Pharmaceuticals

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule active

    1 trial

  16. Ibezapolstat

    Acurx Pharmaceuticals

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  17. Ibrutinib

    United Therapeutics Europe Ltd

    Asymptomatic COVID-19 Infection Laboratory-Confirmed

    phase 2 small molecule terminated

    1 trial

  18. Imdusiran

    Arbutus Biopharma Corp

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  19. Imdusiran (AB-729)

    Arbutus Biopharma Corp

    Chronic Hepatitis B

    phase 2 small molecule active

    1 trial

  20. Imdusiran, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Arbutus Biopharma Corp

    Chronic HBV Infection

    phase 2 small molecule active

    1 trial

  21. Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 small molecule completed

    1 trial

  22. Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

    Takeda

    Immune Thrombocytopenic Purpura (ITP)

    phase 2 small molecule completed

    1 trial

  23. Immunization with P. vivax irradiated sporozoites

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria

    phase 2 mab completed

    1 trial

  24. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  25. Interactive injection and sexual risk intervention

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  26. Interferon Beta-1B

    The University of Hong Kong

    COVID

    phase 2 small molecule completed

    1 trial

  27. Intervention Condition

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  28. Ixazomib 1 MG

    Takeda

    Human Immunodeficiency Virus (HIV)

    phase 2 small molecule completed

    1 trial

  29. JNJ-73763989

    Janssen Cilag International NV

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  30. KAE609

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  31. KAF156

    Novartis Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  32. KAF156

    Novartis Pharmaceuticals

    Acute Uncomplicated Plasmodium Falciparum Malaria

    phase 2 small molecule completed

    1 trial

  33. LENALIDOMIDE, PYRIMETHAMINE, TOPIRAMATE

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  34. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  35. LP-98 20 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule active

    1 trial

  36. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  37. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  38. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    COVID-19

    phase 2 small molecule completed

    1 trial

  39. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  40. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  41. MEDI8897

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  42. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  43. MMV390048 40mg

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  44. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  45. MRx-4DP0004

    4D Molecular Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  46. Maribavir

    Takeda

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  47. Mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID-19

    phase 2 small molecule completed

    3 trials

  48. Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab on hold

    1 trial

Frequently asked questions

How many infectious disease Phase II programs exist?

375 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.